AMENDMENT NO. 3 TO LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • August 2nd, 2019 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 3 (“Amendment No. 3”) to LICENSING AND ASSIGNMENT AGREEMENT, made and entered into the 6th day of October, 2017 (“Amendment No. 3 Effective Date”) by and between Satsuma Pharmaceuticals, Inc., having its principal place of business at 395 Oyster Point Boulevard, South San Francisco, CA 94080, USA (“Company”) and Shin Nippon Biomedical Laboratories, Ltd., having its principal place of business at 2438, Miyanoura-cho, Kagoshima-shi, Kagoshima-ken, Japan (“SNBL”). Company and SNBL are collectively the “Parties”.
AMENDMENT NO. l TO LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • August 16th, 2019 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. l (“Amendment No. l”) to the Licensing and Assignment Agreement by and between Satsuma Pharmaceuticals, Inc. (“Company”) and Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) of June 30, 2016 (the “Agreement”) is dated as of January 13, 2017 (“Amendment No. l Effective Date”)
AMENDMENT NO. 2 TO LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • August 2nd, 2019 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 2 (“Amendment No. 2”) to the Licensing and Assignment Agreement by and between Satsuma Pharmaceuticals, Inc. (“Company”) and Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) of June 30, 2016 (the “Agreement”) is dated as of April 27, 2017 (“Amendment No. 2 Effective Date”)
LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • August 16th, 2019 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS LICENSING AND ASSIGNMENT AGREEMENT (this “Agreement”) is effective as of June 30, 2016 (the “Effective Date”) by and between Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation with a principal place of business at 2438 Miyanouracho, Kagoshima-shi, Kagoshima-ken 891-1394, Japan (“SNBL”), and Satsuma Pharmaceuticals, Inc., a Delaware company (“SATSUMA”), and amends and restates in its entirety that certain Licensing and Assignment Agreement executed on or about June 30, 2016 by SNBL and SATSUMA (the “Original Agreement”). In this Agreement, either SNBL or SATSUMA may be referred to individually as a “Party”, or collectively as the “Parties”.
AMENDMENT NO.4 TO LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • August 11th, 2020 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No.4 (“Amendment No.4”) to the Licensing and Assignment Agreement by and between Satsuma Pharmaceuticals, Inc. (“Company”) and Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) of June 30, 2016 (the “Agreement”) is dated as of May 25, 2020 (“Amendment No.4 Effective Date”).
NON-EXCLUSIVE ALFALFA LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • January 7th, 2015 • S&W Seed Co • Agricultural production-crops • Delaware
This Non-Exclusive Alfalfa Licensing and Assignment Agreement (including all Exhibits hereto, as amended, modified or supplemented from time to time in accordance with its terms, the "Agreement") is entered into this 31st day of December, 2014, by and between Pioneer Hi-Bred International, Inc., having an address at 7100 NW 62nd Avenue, Johnston, Iowa 50131-1014 (the licensee, hereafter "Pioneer"), and S&W Seed Company, having an address at 25552 South Butte Avenue, Five Points, California 93624 (hereinafter "Licensor") (Pioneer and Licensor, hereinafter, are referred to each individually as a "Party" and together as the "Parties").
